SCHEMBL2647289

SCHEMBL2647289

CC=Cc1c(C(C)C)cc(-c2ccc(F)cc2OCc2ccccc2)c(CO)c1C(C)C

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
CYP11B1 P15538 2/20 0.36
CYP11B2 P19099 2/20 0.36
CDK2 P24941 4/20 0.35
CDK9 P50750 4/20 0.35
CCNT1 O60563 3/20 0.35
GPBAR1 Q8TDU6 2/20 0.35
CCNE1 P24864 1/20 0.35
PTGER1 P34995 2/20 0.35
AR P10275 1/20 0.35
CCNA2 P20248 2/20 0.35
CCNA1 P78396 2/20 0.35
FFAR1 O14842 2/20 0.34
AKR1C3 P42330 1/20 0.34
USP2 O75604 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
PPARG P37231 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2648946 0.79 GCGR (0.44) FFAR4L3MBTL1CYP11B1CYP11B2CDK2
SCHEMBL2648389 0.76 L3MBTL1 (0.40) FFAR4L3MBTL1CYP11B1CYP11B2CDK2
SCHEMBL2648392 0.76 L3MBTL1 (0.40) FFAR4L3MBTL1CYP11B1CYP11B2CDK2
SCHEMBL2647497 0.75 FFAR4 (0.39) FFAR4L3MBTL1CYP11B1CYP11B2CDK2
SCHEMBL2647496 0.75 FFAR4 (0.39) FFAR4L3MBTL1CYP11B1CYP11B2CDK2
SCHEMBL2646478 0.73 L3MBTL1 (0.47) FFAR4L3MBTL1CYP11B1CYP11B2CDK2
SCHEMBL2647294 0.72 GLRA1 (0.38)
SCHEMBL2647845 0.70 L3MBTL1 (0.43) FFAR4L3MBTL1CYP11B1CYP11B2CDK2
SCHEMBL2648631 0.69 GCGR (0.57) FFAR4L3MBTL1CYP11B1CYP11B2CDK2
SCHEMBL2648891 0.69 L3MBTL1 (0.46) FFAR4L3MBTL1CYP11B1CYP11B2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218431-B1 GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES BAYER CORPORATION 2001-04-17 US disclosed